• Combination Therapy

    Regenetek’s Combination Stem Cell and Vascular Therapy

    read more
  • Regenerative Medicine

    ‎The Most Current Information Available from Leading Scientists and Clinical Trials World-wide

    read more
  • Patient Registry Software

    Application of Technology to Make Any Size of Study Self-Managing and Affordable

    read more
  • Neurodegenerative Disorders

    The Latest Updates on Diseases Treatable Through Regenerative Medicine

    read more
  • Topical Commentary

    Opinions from Regenetek and Leading Authorities in Regenerative Medicine

    read more

Patient Registry Software

Experimental Medical Therapies Need to be Tracked

With so many cell-based therapies being performed world-wide, there must be a better way of tracking results. The key to turning this area of medicine from medical tourism into medical research is to enroll patients into actual IRB approved clinical studies so scientists can learn what works and what doesn’t work. Many clinicians agree that this is the only way for the field to progress. It is already conceded that many physician-scientists in the stem cell field are employed by companies who are pursuing revenues in a way that patient outcomes aren’t studied and the knowledge of what is working isn’t passed on to the rest of the medical community. Many types of treatments can already be demonstrated to work well but there is no scientific basis on which data can provide evidence of this. As a result, confusion reigns in the patient/consumer community and serious scientists outside of the private sector remain vocal opponents of stem cell therapies altogether. The fact is that if patients are to be truly helped, good clinical trials that follow basic scientific guidelines must become standard practice.

Overview of Regenetek Software

This software allows any therapeutic outcome to be followed for years. Study sizes can be as few as one. Both researchers and patients are given their own dashboard views and functionality. The software automatically tracks patient results and even allows the patient to upload ancillary medical records. Various unique features: tracks patient locations if they move, applies bias reduction models, automatically searches and tracks other interventional therapies for the same disease type and creates cohort comparisons in templated charts, applies standardized disability scales to diseases to create surveys, aggregates patient populations from different centers, automatically populates study data in charts and within templated study design formats for easy publishing, and has a feature to allow direct communication with the PI to report adverse events. Features can be turned on or off as required. The software is even available as an i-phone app. Most importantly, this application of technology makes any size of study affordable in an era when obtaining research funding is becoming more challenging.

Written by Doug Broeska

Doug Broeska is a PhD Medical Researcher and CEO of Regenetek Inc, a Canadian Biotech Research firm working with several hospitals and clinics world-wide to develop medical procedural protocols for neurodegenerative disease management.